Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BNXTFNASDAQ:ELDNNASDAQ:NVCTNASDAQ:OABI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNXTFBioNxt Solutions$0.39-4.8%$0.36$0.11▼$0.43$45.15M0.811,759 shs4,200 shsELDNEledon Pharmaceuticals$2.72-2.2%$3.04$2.30▼$5.54$162.88M-0.17274,584 shs244,846 shsNVCTNuvectis Pharma$8.13+1.0%$9.28$4.44▼$11.80$169.86M-0.16129,271 shs93,851 shsOABIOmniAb$1.59-3.6%$1.60$1.22▼$4.96$194.20M-0.02665,505 shs1.08 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNXTFBioNxt Solutions0.00%-1.04%+2.63%-9.89%+64.07%ELDNEledon Pharmaceuticals0.00%-5.23%-9.93%-22.51%+4.21%NVCTNuvectis Pharma0.00%-3.33%-18.29%-20.29%+26.05%OABIOmniAb0.00%-10.67%+12.77%-37.15%-62.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNXTFBioNxt SolutionsN/AN/AN/AN/AN/AN/AN/AN/AELDNEledon Pharmaceuticals2.7103 of 5 stars3.54.00.00.02.81.70.0NVCTNuvectis Pharma2.8689 of 5 stars3.50.00.00.02.85.00.6OABIOmniAb3.1319 of 5 stars3.51.00.00.03.23.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNXTFBioNxt Solutions 0.00N/AN/AN/AELDNEledon Pharmaceuticals 3.00Buy$9.00230.88% UpsideNVCTNuvectis Pharma 3.00Buy$17.00109.10% UpsideOABIOmniAb 3.00Buy$7.00340.25% UpsideCurrent Analyst Ratings BreakdownLatest BNXTF, NVCT, ELDN, and OABI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$9.005/12/2025OABIOmniAbBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/30/2025NVCTNuvectis PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $15.004/2/2025NVCTNuvectis PharmaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$17.003/27/2025OABIOmniAbRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$7.00 ➝ $4.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNXTFBioNxt Solutions$280K161.24N/AN/A($0.04) per share-9.75ELDNEledon PharmaceuticalsN/AN/AN/AN/A$1.98 per shareN/ANVCTNuvectis PharmaN/AN/AN/AN/A$0.50 per shareN/AOABIOmniAb$26.39M7.36N/AN/A$2.37 per share0.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNXTFBioNxt Solutions-$5.72M-$0.040.00∞N/A-15,638.71%N/A-683.78%N/AELDNEledon Pharmaceuticals-$36.18M-$2.100.00N/AN/AN/A-79.54%-41.62%8/18/2025 (Estimated)NVCTNuvectis Pharma-$19M-$1.130.00N/AN/AN/A-148.83%-95.60%8/5/2025 (Estimated)OABIOmniAb-$62.03M-$0.580.00N/AN/A-229.11%-21.37%-18.84%8/6/2025 (Estimated)Latest BNXTF, NVCT, ELDN, and OABI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ELDNEledon Pharmaceuticals-$0.28-$0.08+$0.20-$0.08N/AN/A5/8/2025Q1 2025OABIOmniAb-$0.17-$0.17N/A-$0.17$4.49 million$4.15 million5/6/2025Q1 2025NVCTNuvectis Pharma-$0.30-$0.27+$0.03-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNXTFBioNxt SolutionsN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/AOABIOmniAbN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNXTFBioNxt SolutionsN/A0.040.04ELDNEledon PharmaceuticalsN/A13.9013.91NVCTNuvectis PharmaN/A3.283.28OABIOmniAbN/A4.704.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNXTFBioNxt SolutionsN/AELDNEledon Pharmaceuticals56.77%NVCTNuvectis Pharma96.77%OABIOmniAb72.08%Insider OwnershipCompanyInsider OwnershipBNXTFBioNxt SolutionsN/AELDNEledon Pharmaceuticals12.30%NVCTNuvectis Pharma30.52%OABIOmniAb8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNXTFBioNxt Solutions20115.76 millionN/ANot OptionableELDNEledon Pharmaceuticals1059.88 million52.52 millionOptionableNVCTNuvectis Pharma820.89 million14.52 millionNot OptionableOABIOmniAb7122.14 million111.63 millionOptionableBNXTF, NVCT, ELDN, and OABI HeadlinesRecent News About These CompaniesOmniAb, Inc. (NASDAQ:OABI) Shares Sold by Chicago Capital LLCJune 17, 2025 | marketbeat.comOmniAb, Inc. (NASDAQ:OABI) Short Interest Down 15.8% in MayJune 3, 2025 | marketbeat.comChairman of OmniAb Picks Up 3.0% More StockMay 19, 2025 | uk.finance.yahoo.comOmniAb, Inc. (NASDAQ:OABI) Director Steven Love Purchases 25,000 SharesMay 15, 2025 | insidertrades.comInsider Buying: OmniAb, Inc. (NASDAQ:OABI) Director Buys 65,000 Shares of StockMay 14, 2025 | insidertrades.comOmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston SummitMay 13, 2025 | businesswire.comIs OmniAb, Inc. (OABI) the Low Risk High Reward Stock Set to Triple by 2030?May 10, 2025 | insidermonkey.comOmniAb, Inc. (NASDAQ:OABI) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comOmniAb, Inc. (OABI) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comOmniAb Introduces the xPloration® Partner Access ProgramMay 9, 2025 | tmcnet.comOmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue EstimatesMay 8, 2025 | zacks.comOmniAb Reports First Quarter 2025 Financial Results and Business HighlightsMay 8, 2025 | businesswire.comVERAXA Biotech AG and OmniAb, Inc. Announce Co-Discovery Alliance for Novel Bispecific Antibody Drug Conjugate Program Targeting Solid TumorsMay 5, 2025 | quiverquant.comVERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate ProgramMay 5, 2025 | globenewswire.comCompanies Like OmniAb (NASDAQ:OABI) Are In A Position To Invest In GrowthApril 25, 2025 | finance.yahoo.comOmniAb Announces Two New Appointments to its Board of DirectorsApril 21, 2025 | finance.yahoo.comOmniAb Appoints New Directors to BoardApril 21, 2025 | tipranks.comLeerink Partners Sticks to Their Buy Rating for OmniAb (OABI)April 20, 2025 | markets.businessinsider.comKurt A. Gustafson Sells 11,963 Shares of OmniAb, Inc. (NASDAQ:OABI) StockApril 2, 2025 | insidertrades.comAnalyst Forecasts Just Became More Bearish On OmniAb, Inc. (NASDAQ:OABI)March 29, 2025 | uk.finance.yahoo.comOmniAb price target lowered to $4 from $7 at RBC CapitalMarch 27, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBNXTF, NVCT, ELDN, and OABI Company DescriptionsBioNxt Solutions OTCMKTS:BNXTF$0.39 -0.02 (-4.81%) As of 06/20/2025 03:50 PM EasternBioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.Eledon Pharmaceuticals NASDAQ:ELDN$2.72 -0.06 (-2.16%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.72 -0.01 (-0.18%) As of 06/20/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Nuvectis Pharma NASDAQ:NVCT$8.13 +0.08 (+0.99%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$8.07 -0.06 (-0.74%) As of 06/20/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.OmniAb NASDAQ:OABI$1.59 -0.06 (-3.64%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.58 -0.01 (-0.31%) As of 06/20/2025 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
